Liver Cancer Treatments

Find Liver Cancer Treatments

Brand Name

Lipiodol

Generic Name

Ethiodized

View Brand Information

FDA approval date: March 21, 2014

Form: Injection

What is Lipiodol (Ethiodized)?

Lipiodol is an oil-based radio-opaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma Lipiodol is an oil-based radiopaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma

Approved To Treat

Liver Cancer

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Phase I/II Study of Tebentafusp-tebn in Combination With Liver-Directed Therapies for the Treatment of Metastatic Uveal Melanoma

Enrollment Status: Recruiting

Publish Date: June 16, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A\*0201 positive patients with metastatic uveal melanoma. In Part 1 of the study, the Prinicipal Investigator will investigate the safety and efficacy of tebentafusp-tebn in combination with hepatic IE in patients with a low to...

Hepatic Arterial Infusion Chemotherapy Plus Sintilimab and Bevacizumab Versus Transarterial Chemoembolization Plus Sintilimab and Bevacizumab for Intermediate-Stage Hepatocellular Carcinoma Beyond the Up-To-Seven Criteria：A Prospective, Randomized, Controlled Trial

Enrollment Status: Recruiting

Publish Date: May 22, 2026

Intervention Type: Procedure

Study Phase: Phase 3

Objective: To compare Progression-Free Survival (PFS) between the two arms as evaluated by mRECIST. Enrollment: A total of 300 patients will be randomized at a 1:1 ratio to the treatment groups. The study aims to provide high-level clinical evidence for optimizing treatment strategies for this specific subgroup of HCC patients.

Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment: a Pilot Study of 15 Patients

Enrollment Status: Recruiting

Publish Date: May 05, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: The goal of this clinical trial is to evaluate the safety of arterial embolization using Lipiodol® in patients with symptomatic hand osteoarthritis refractory to conventional treatment. It will also learn about the efficacy of arterial embolization with Lipiodol® in reducing pain and improving hand function. The main questions it aims to answer are: * What are the side effects and complications as...

View All Clinical Trials

Related Latest Advances

A Dual-Imaging Fluorescent and Iodinated Thermosensitive Hydrogel for Image-Guided Surgery of Pulmonary Nodules.

Journal: ACS applied bio materials

Published: May 26, 2026

Value of dual-energy CT in assessing therapeutic response after TACE for hepatocellular carcinoma: A retrospective comparative study with conventional CT.

Journal: European journal of radiology

Published: May 13, 2026

Correction to: Retrospective Comparison of Short and Mid Term Performance of 200 µm Polyethylene Glycol Microspheres vs Ethiodized Oil Emulsion for Genicular Artery Embolization in Symptomatic Knee Osteoarthritis.

Journal: Cardiovascular and interventional radiology

Published: May 12, 2026

View All Latest Advances

Brand Information

LIPIODOL (ethiodized oil)

1INDICATIONS AND USAGE

Lipiodol is an oil-based radio-opaque contrast agent indicated for:

hysterosalpingography in adults
lymphography in adult and pediatric patients
selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)

2DOSAGE FORMS AND STRENGTHS

Each milliliter of Lipiodol contains 480 mg/mL of Iodine organically combined with ethyl esters of fatty acids of poppy seed oil.

3CONTRAINDICATIONS

Lipiodol is contraindicated in patients with hypersensitivity to Lipiodol, hyperthyroidism, traumatic injuries, recent hemorrhage or bleeding.

Hysterosalpingography

Lipiodol hysterosalpingography is contraindicated in pregnancy, acute pelvic inflammatory disease, marked cervical erosion, endocervicitis and intrauterine bleeding, in the immediate pre-or postmenstrual phase, and within 30 days of curettage or conization or patients with known or suspected reproductive tract neoplasia due to the risk of peritoneal spread of neoplasm. [see

Lymphography

Lipiodol Lymphography is contraindicated in patients with a right to left cardiac shunt, advanced pulmonary disease, tissue trauma or hemorrhage advanced neoplastic disease with expected lymphatic obstruction, previous surgery interrupting the lymphatic system, radiation therapy to the examined area.

Selective Hepatic Intra-arterial Use Patients with HCC

Lipiodol use is contraindicated in areas of the liver where the bile ducts are dilated unless external biliary drainage was performed before injection.

4OVERDOSAGE

Overdose may lead to respiratory, cardiac or cerebral complications, which can potentially be fatal. Microembolisms to multiple organs may occur more frequently after overdose. Promptly initiate symptomatic treatment and support of vital functions.

5DESCRIPTION

Lipiodol, ethiodized oil injection, is a sterile injectable radio-opaque agent. Each milliliter contains 480 mg of Iodine organically combined with ethyl esters of fatty acids of poppy seed oil. The precise structure of Lipiodol is unknown.

Lipiodol is a sterile, clear, pale yellow to amber colored oil. Lipiodol has a viscosity of 34 – 70 mPa·s at 20°C, and a density of 1.28 g/cm

6HOW SUPPLIED/STORAGE AND HANDLING

Lipiodol is supplied in a box of one 10 mL ampoule, NDC 67684-1901-1.

Lipiodol is supplied in a box of one 10 mL vial, NDC 67684-1901-2.

Store at controlled room temperature 15°-30°C (59°-86°F) [see USP, Controlled Room Temperature (CRT)]. Protect from light. Remove from carton only upon use.

7PATIENT COUNSELING INFORMATION

Hypersensitivity Reactions

Advise the patient concerning the risk of hypersensitivity reactions that can occur both during and after Lipiodol administration. Advise

Thyroid Dysfunction

Advise patients concerning the risk of hyper- or hypothyroidism flowing the use of Lipiodol due to ethiodized oil remaining in the body